Insulin Resistance - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Insulin Resistance - Pipeline Review, H1 2015’, provides an overview of the Insulin Resistance’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Insulin Resistance
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Insulin Resistance and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Insulin Resistance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Insulin Resistance pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Insulin Resistance
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insulin Resistance pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Insulin Resistance Overview
- Therapeutics Development
- Pipeline Products for Insulin Resistance - Overview
- Pipeline Products for Insulin Resistance - Comparative Analysis
- Insulin Resistance - Therapeutics under Development by Companies
- Insulin Resistance - Therapeutics under Investigation by Universities/Institutes
- Insulin Resistance - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Insulin Resistance - Products under Development by Companies
- Insulin Resistance - Products under Investigation by Universities/Institutes
- Insulin Resistance - Companies Involved in Therapeutics Development
- AUS Bio Limited
- Genfit SA
- GlaxoSmithKline plc
- Hadasit Medical Research Services & Development Ltd
- Mertiva AB
- Mochida Pharmaceutical Co., Ltd.
- Novartis AG
- Prometheon Pharma, LLC
- Sanofi
- Thetis Pharmaceuticals LLC
- Insulin Resistance - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- 6860766 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BVS-857 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Englerin A - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GFT-505 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MD-960 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PEG-Catalase - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Peptide for Obesity and Insulin Resistance - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SAR-088 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SERX-1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule for Hypertension and Insulin Resistance - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TP-113 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Insulin Resistance - Recent Pipeline Updates
- Insulin Resistance - Dormant Projects
- Insulin Resistance - Product Development Milestones
- Featured News & Press Releases
- Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Insulin Resistance, H1 2015
- Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Investigation by Universities/Institutes, H1 2015
- Insulin Resistance - Pipeline by AUS Bio Limited, H1 2015
- Insulin Resistance - Pipeline by Genfit SA, H1 2015
- Insulin Resistance - Pipeline by GlaxoSmithKline plc, H1 2015
- Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015
- Insulin Resistance - Pipeline by Mertiva AB, H1 2015
- Insulin Resistance - Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015
- Insulin Resistance - Pipeline by Novartis AG, H1 2015
- Insulin Resistance - Pipeline by Prometheon Pharma, LLC, H1 2015
- Insulin Resistance - Pipeline by Sanofi, H1 2015
- Insulin Resistance - Pipeline by Thetis Pharmaceuticals LLC, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Insulin Resistance Therapeutics - Recent Pipeline Updates, H1 2015
- Insulin Resistance - Dormant Projects, H1 2015
- List of Figures
- Number of Products under Development for Insulin Resistance, H1 2015
- Number of Products under Development for Insulin Resistance - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Clinical Stage Development, H1 2015
- Comparative Analysis by Early Stage Products, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015
- Number of Products by Stage and Top 10 Molecule Types, H1 2015